Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control. A combination of the two agents in a single inhaler is beneficial with regard to ease of administration and patient compliance. Various ICS-LABA formulations are available across various countries in the world, one among them being formoterol-fluticasone. Both formoterol and fluticasone have pharmacologic peculiarities which places the combination in a uniquely advantageous position when it comes to asthma therapy. The present review focuses on some of the, hitherto, less explored aspects of this combination inhaler such as real-world efficacy, impact on budget allocation, results of switch-over therapy, and potential to improve adherence to asthma treatment. It also provides practical recommendations on positioning it in real-world asthma management.

中文翻译：

---

吸入福莫特罗-氟替卡松单次吸入治疗哮喘：真实世界的疗效、预算影响和提高依从性的潜力

哮喘是影响人类气道的最常见的慢性疾病，并且具有日益增加的全球疾病负担。吸入性皮质类固醇 (ICS) 是哮喘的一线治疗选择，添加长效 β2-激动剂 (LABA) 已被证明可以改善哮喘控制。在单一吸入器中的两种药剂的组合在易于给药和患者依从性方面是有益的。各种 ICS-LABA 制剂可在世界各个国家/地区使用，其中之一是福莫特罗-氟替卡松。福莫特罗和氟替卡松都具有药理学特性，这使得它们在哮喘治疗方面处于独特的优势地位。本综述侧重于该组合吸入器迄今为止尚未探索的一些方面，例如真实世界的功效、对预算分配、转换治疗结果以及改善哮喘治疗依从性的潜力的影响。它还提供了将其定位在现实世界哮喘管理中的实用建议。